Skip to main content

Published locations for Meta-analysis favors SubQ infliximab biosimilar over vedolizumab in Crohn’s disease

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Meta-analysis favors SubQ infliximab biosimilar over vedolizumab in Crohn’s disease

User login

  • Reset your password
  • /content/meta-analysis-favors-subq-infliximab-biosimilar-over-vedolizumab-crohns-disease
  • /gihepnews/article/252172/gastroenterology/meta-analysis-favors-subq-infliximab-biosimilar-over
  • /internalmedicinenews/article/252172/gastroenterology/meta-analysis-favors-subq-infliximab-biosimilar
  • /internalmedicine/article/252172/gastroenterology/meta-analysis-favors-subq-infliximab-biosimilar